![]() That’s because Predicta Med doesn’t do the actual diagnosis it’s a decision support system that presents results to primary-care physicians who then make the call – usually to refer a patient to a gastrointestinal specialist. The company has already aggregated 2.7 million EMR data points and 1.7 million claims records in Israel and will expand that in the US as it gets closer to launch – target date is the end of 2022 and, for the current version of the product, FDA approval is not required. Predicta Med starts by aggregating data from two main sources: electronic medical records (EMRs) and insurance claims. Predicta Med founder Shlomit Steinberg-Koch. (By way of comparison, COPD costs the American healthcare system some $50 billion cancer costs $125 billion a year.) “It’s an unmet need.”Ī 2019 report found that over $100 billion is spent annually on diagnosing and treating inflammatory conditions like Crohn’s or fibromyalgia. “It takes an average of four years and four different doctors to correctly diagnose an autoimmune illness,” Steinberg-Koch tells ISRAEL21c. It also diagnoses rheumatoid arthritis, psoriatic arthritis, multiple sclerosis and lupus with an average 84% accuracy. Predicta Med, as its name implies, uses artificial intelligence and machine learning to help physicians determine if they’re looking at Crohn’s disease, ulcerative colitis or celiac disease. So she brought in a second partner, Benny Getz, previously the CTO of cybersecurity startup Kayhut, to add the necessary technical capabilities to the team. The eight-person Ramat Gan-based company has raised $2 million so far and is about to close a full seed round.Īlthough Steinberg-Koch has a bachelor’s degree in biomedical engineering, at Mazor she had moved more into a product management role. Moshe Shoham, Nadav’s father, was the first investor. Steinberg-Koch started the company in 2020, after Mazor was acquired by Medtronic for $1.6 billion in 2018. ![]() Autoimmune diseases tend to be incurable although not fatal. That “something” turned into Predicta Med with an expanded mandate: to help primary-care physicians diagnose not just celiac disease but six other hard-to-identify autoimmune conditions.Īutoimmune diseases are those in which the immune system, instead of attacking diseases and infections, attacks the body itself. But then I won the competition and I said, ‘OK, now I really must do something with this.’” It started as a memorial project to Nadav. “One of the challenges was to detect celiac disease,” Steinberg-Koch recalls. The Israeli HMO Maccabi gave participants anonymized patient data. ![]() In 2019, Steinberg-Koch participated in a medical-technology hackathon. ![]() While this wasn’t connected to the tragedy, it was something that he and Steinberg-Koch spoke about frequently. Nadav Shoham, Steinberg-Koch’s colleague and good friend from her previous employer, Mazor Robotics, was trying to cross a high-altitude pass in the Annapurna region of the Nepalese Himalayas in 2015 when he was caught in an intense snowstorm and died. Shlomit Steinberg-Koch was working through a personal tragedy when the idea for her new startup, Predicta Med, hit her like a landslide. ![]()
0 Comments
Leave a Reply. |